Acumen Pharma posts smaller-than-expected 2025 loss on lower G&A costs

Acumen Pharmaceuticals

26/03/2026 11:10

Overview

U.S. Alzheimer's drug developer's 2025 net loss and operating loss both narrower than analyst estimates

R&D expenses rose on higher costs for ALTITUDE-AD trial and pipeline expansion

Company raised $35.75 mln in March 2026 private placement to advance EBD program

Outlook

Company expects topline results from ALTITUDE-AD Phase 2 study in late 2026

Acumen targets IND filing for lead EBD program candidate in mid-2027

Cash expected to support clinical and operational activities into early 2027

Result Drivers

R&D SPENDING - Higher R&D expenses driven by increased manufacturing and materials costs for ALTITUDE-AD trial and EBD program expansion

COST CONTROL - Lower G&A expenses due to reductions in recruiting, insurance, and consulting costs

PIPELINE FUNDING - $35.75 mln private placement in March 2026 to advance EBD portfolio after strong preclinical data

Company press release: ID:nGNXbGVlZq

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
FY Net Income
Beat
-$121.34 mln
-$124.77 mln (6 Analysts)
FY Income From Operations
Beat
-$123.83 mln
-$127.89 mln (6 Analysts)
FY Basic EPS
-$2
FY Operating Expenses
$123.83 mln


Analyst Coverage

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy."

Wall Street's median 12-month price target for Acumen Pharmaceuticals Inc is $8.00, about 204.2% above its March 25 closing price of $2.63

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)